---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-002781"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:46:40.093617+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma reports FY 2025 revenue $36.3M (+4.1% YoY), net loss $5.98M

## Summary
- Revenue $36.31M vs $34.87M in 2024; gross profit $12.26M up from $10.67M.
- Net loss widened to $5.98M from $5.13M, including $1.75M non-cash impairment charge.
- Launched 9 new generic drugs in 2025, portfolio now 71 products; 12 more planned in 2026.
- Raised $2.46M gross via registered direct offering to expand sales operations.
- Cost-reduction initiatives expected to cut G&A by $2M-$3M in 2026.

## SEC filing metadata
- accession: 0001683168-26-002781
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002781/0001683168-26-002781-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002781/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-002781
- JSON: https://secwatch.observer/filing/0001683168-26-002781.json
- Plain text: https://secwatch.observer/filing/0001683168-26-002781.txt

## Key facts
- Earnings Releases
  Sunshine Biopharma Inc. reported the year ended December 31, 2025 results: revenue $36.3 million.
  - Period: the year ended December 31, 2025
  - Revenue: $36.3 million
  - Result: reported results
  source text: specific reference in such filing. --- EX-99.1 (PRESS RELEASE) --- EX-99.1 2 sunshine_ex9901.htm PRESS RELEASE Exhibit 99.1 Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year FORT LAUDERDALE, FL / ACCESSWIRE / April 6, 2026 — Sunshine Biopharma Inc. (NASDAQ: SBFM) (“Sunshine Biopharma” or the “Company”), a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002781/0001683168-26-002781-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.